Psychedelic Spotlight Interview
CEO of Entheon Biomedical, Timothy Ko, discusses...
Benzinga – Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee
Entheon Biomedical Corp. announced the launch of...
Benzinga – Entheon Launches Psychedelics Pre-Screening Genetic Test
Entheon Launches Psychedelics Pre-Screening...
BioSpace Movers & Shakers
Gyroscope Therapeutics – Jessica Stitt was named...
Bloomberg
Entheon Biomedical Announces Nancy Maher,...
Psychedelic Therapeutics Reviewed by NeuroPerspective
SAN DIEGO, March 2, 2021 /PRNewswire/...
Psychedelic Special Task Force – Report on Psychedelics
Numinus and MAPS reach trial milestone In a...
Psychedelic Summit Talks Legalization Prep | Cannabis Culture
CANNABIS CULTURE – Speakers from across North...
The London Free Press – “Western grad’s own trauma leads to research on improved treatment”
A double tragedy has sent a Western University...
Datac – New clinical trial to explore DMT as treatment for substance use disorders
The Canadian R&D company Entheon Biomedical...
Humble & Fred Radio Show (@1:26:45)
Jason Parsons talks about the end of USS / Rebel...
Benzinga – Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment
Psychedelics biotech company Entheon Biomedical...
Technology Networks
Substance use disorders have a debilitating...
Tonic Magazine
Using Psychedelics To Treat Addictions 5...
INN: Psychedelics Outlook 2021: How Far Can This Industry Go?
Click here to read the previous psychedelics...
Benzinga – Entheon Biomedical And Psygen Labs Inc.’s DMT Drug Supply Agreement
Thousands of traders just like you are using...
INN: Psychedelic Trends 2020: The Heat is On
2020 marked the beginning of the psychedelics...
Benzinga – Psyched: Canada Allows Psilocybin Use For Healthcare Pros, UK Begins DMT Trials, Cybin To Purchase Adelia
Psyched: Canada Allows Psilocybin Use For...
Tonic Podcast w/ Jamie Bussin
Magazine publisher, Jamie Bussin hosts this...
Benzinga – Imperial College Of London To Study Illegal Psychedelic Compound In First-Ever Clinical Trial
Clinical trials on the hallucinogenic drug DMT...
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Proud to announce we have strategically invested in Wonder Scientific, a very talented group of researchers and product development experts who are creating custom, naturally derived, APIs (active pharmaceutical ingredients) for the clinical and commercial demand for psychedelics.
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial, Centre for Human Drug Research led DMT study to start in 2021
The Green Rush Podcast
http://greenrushpodcast.net/2020/12/10/timothy-ko-...
Truffle Report – Truffle Talk: Timothy Ko Of Entheon Biomedical
https://www.truffle.report/truffle-talk-timothy-ko...
Globe & Mail – market movers
https://www.theglobeandmail.com/investing/markets/...
Benzinga – Psyched: Oregon Legalizes Psilocybin, Washington DC Decriminalizes Psychedelics, Cybin And Entheon To Go Public
https://www.benzinga.com/markets/cannabis/20/11/18...
Entheon Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
Original Source - Newsfile Corp. Vancouver,...
When Will Psychedelics be Legal in the United States?
With all eyes on the American election, we are sure that those in the psychedelic medicine sphere wonder what this could mean for the future of psychedelic medicine in the United States. Here’s our stance.
MPV annonce l’approbation conditionnelle de sa transaction avec Entheon Biomedical Corp. par le CSE
MONTRÉAL, 28 oct. 2020 (GLOBE NEWSWIRE) --...
MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp.
MPV Exploration Inc. (“MPV” or the “Company”) is pleased to announce that further to its news releases dated July 2, 2020 and September 10, 2020 (the “Initial News Releases”), the Company has received conditional approval from the Canadian Securities Exchange (“CSE”)
Canada Calls for Reformative Action in the Opioid Crisis
Canada appears to be taking a progressive yet patchworked community healthcare approach to alleviating the current opioid and substance-use crisis. But will this alleviate or reduce the number of barriers to safe and effective treatment, or do Canadian patients need and deserve more?
PsyTech Article/Interview
https://psytechglobal.com/timothy-ko-psychedelic-a...
Benzinga – Research Efforts From Entheon Biomedical Suggest Psychedelics’ Potential In Treating Chronic Addictions
https://www.benzinga.com/markets/cannabis/20/10/17...
The Entheon Approach – Microdose
https://microdose.buzz/the-entheon-approach-dmt-fo...
The steep price of not treating Canada’s opioid crisis
The toll of the opioid crisis in Canada is multi-layered, affecting family and home life and rippling outward to our civic institutions and the economy as a whole. Learn more about these effects and how Entheon Biomedical sees hope through psychedelic-assisted therapy.
Psychedelics and Their Place in Modern Pharmacology, a Q&A with Andrew Hegle, Ph.D.
See why Entheon’s Chief Science Officer and Director of Operations sees psychedelics are a prominent tool that we should be leveraging for mental health treatments.
Psychedelics: Why Now, and Finding the Best Approach, a Q&A with Yaron Eshel
What made Entheon stand out to this Project Manager and why does he call the company “The FDAs Dream”? Those questions and more, answered here.
Opioid Crisis in Canada—the Communities it Disproportionately Affects
Opioids don’t discriminate—opioid misuse affects all Canadians. Read researcher Jessica Cadoch’s article on how access to treatments for opioid dependency serves communities disproportionately, and how psychedelics offer hope for a more fair, effective and democratic solution.
Is 5-MeO-DMT an accompaniment to the treatment of substance use disorders?
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic substance that can be found in plants (Pachter et al. 1959), the secretion of the Incilius Alvarius toad (Weil and Davis 1994), and made synthetically (Hoshino 1936). The substance is well-known for its short-acting properties (depending on the route of administration) with subjective effects summarized in the following soundbite: ‘we are all on
Overview of the worsening opioid crisis in Canada
In the last six months, in the face of the COVID-19 pandemic, we have seen a spike in opioid overdoses, adding more layers of destruction and devastation on an already about isolated, uncertain, and grieving society due to the distancing measures, deaths and job losses that hallmarked this pandemic.